This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Apr 2011

FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer

AstraZeneca received the FDA approval for the orphan drug vandetanib as a treatment of medullary thyroid cancer.

AstraZeneca announced yesterday that the U.S. FDA approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.


"Vandetanib is the only medicine to receive FDA approval specifically for use in patients with advanced medullary thyroid cancer and is the first treatment that AstraZeneca has developed and brought to market under orphan drug designation in the US,” said Howard Hutchinson, Chief Medical Officer, AstraZeneca.


AstraZeneca will work to make vandetanib available to patients as soon as possible. Vandetanib will be dispensed exclusively through the pharmacy business unit of Biologics, Inc

Related News